HepTcell™ is an immunotherapeutic product candidate for treatment of chronic hepatitis B (CHB). If left untreated, CHB can lead to cirrhosis, liver failure and liver cancer. According to World Health Organization estimates, CHB affects approximately 296 million worldwide, and over 800,000 people die annually of complications of the disease. There is no cure for CHB, and currently available medications only control the disease without eradicating the infection.
Immunotherapeutic For Chronic Hepatitis B (CHB) Infections
Mechanism of Action
HepTcell™ is composed of nine synthetic HBV-derived peptides formulated with IC31®, a TLR9-based adjuvant from Valneva SE. The peptides are designed to drive T cell responses against all HBV genotypes in patients of diverse genetic background. Normally, the HBV virus is eliminated through T cell dependent mechanisms but stimulating these responses in chronically infected HBV patients has posed a challenge due to the exhaustion of T cells directed against the virus. HepTcell™ is designed to break this immune tolerance in chronic HBV patients.